WO2021249529A1 - Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications - Google Patents

Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications Download PDF

Info

Publication number
WO2021249529A1
WO2021249529A1 PCT/CN2021/099626 CN2021099626W WO2021249529A1 WO 2021249529 A1 WO2021249529 A1 WO 2021249529A1 CN 2021099626 W CN2021099626 W CN 2021099626W WO 2021249529 A1 WO2021249529 A1 WO 2021249529A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
inden
fluoro
compound
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/099626
Other languages
English (en)
French (fr)
Inventor
Ying Su
Xiaokun ZHANG
Ziwen CHEN
Qiangzhen CHEN
Haishan Wang
Xindao ZHANG
Zhiping ZENG
Lijun Cai
Yuqi Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucmito Pharmaceuticals Co Ltd
Original Assignee
Nucmito Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nucmito Pharmaceuticals Co Ltd filed Critical Nucmito Pharmaceuticals Co Ltd
Priority to KR1020237001096A priority Critical patent/KR20230024976A/ko
Priority to CA3182036A priority patent/CA3182036A1/en
Priority to JP2022576471A priority patent/JP2023529011A/ja
Priority to CN202180055583.6A priority patent/CN116472034B/zh
Priority to US18/001,309 priority patent/US20230234909A1/en
Priority to AU2021287932A priority patent/AU2021287932A1/en
Priority to IL298984A priority patent/IL298984A/en
Priority to EP21822474.9A priority patent/EP4165009A4/en
Publication of WO2021249529A1 publication Critical patent/WO2021249529A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/125—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups
    • C07C59/135—Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/54—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to two or three six-membered aromatic rings
    • C07C211/55—Diphenylamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/68—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/22—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/30—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/30—Sulfides having the sulfur atom of at least one thio group bound to two carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D259/00—Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Definitions

  • an indene compound and a pharmaceutical composition thereof are provided herein. Also provided herein is a method of their use for treating, preventing, or ameliorating one or more symptoms of a fibrotic disease.
  • Fibrosis is the accumulation of extracellular matrix components in organs or tissues, changing their structures and leading to a disruption of normal functions, and, in many cases, ultimately leading to organ failure and death.
  • Hernandez-Gea et al. Annu. Rev. Pathol. 2011, 6, 425-56; Makarev et al., Cell Cycle 2016, 15, 1667-73.
  • Fibrosis can occur in almost any organ or tissue and is associated with a wide variety of diseases, contributing to up to 45%of deaths in the developed world. Mehal et al., Nat. Med. 2011, 17, 552-3; Makarev et al., Cell Cycle 2016, 15, 1667-73.
  • NASH non-alcoholic steatohepatitis
  • hepatocytes fibrosis that can lead to cirrhosis, liver failure, and death.
  • Roenn Clin. Liver Dis. (Hoboken) 2018, 12, 35-6; Sheka et al., JAMA 2020, 323, 1175-83.
  • the stage of liver fibrosis is a strong predictor of clinical outcomes in patients with NASH.
  • R 1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl;
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or heteroaryl; wherein R 2a , R 2b , and R 2c are each independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl;
  • R 3 , R 4 , R 5 , and R 6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C (O) R 1a , -C (O) OR 1a , -C (O) NR 1b R 1c , -C (NR 1a ) NR 1b R 1c , -OR 1a , -OC (O) R 1a , -OC (O) OR 1a , -OC (O) NR 1b R 1c , -OC (NR 1a ) NR 1b R 1c , -OS (O) R 1a , -OS (O) 2 R 1a , -OS (O) NR
  • R A is C 6-14 arylene or heteroarylene
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or -S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6- 14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene, C 2-6 alkenylene, C 3-10 cycloalkylene, or heterocyclylene;
  • each R 1a , R 1b , R 1c , and R 1d is independently hydrogen, deuterium, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or R 1a and R 1c together with the C and N atoms to which they are attached form heterocyclyl; or R 1b and R 1c together with the N atom to which they are attached form heterocyclyl;
  • each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; and (c) -C (O) R a , -C (O) OR
  • each Q a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) -C (O) R e , -C (O) OR e , -C (O) NR f R g , -C (O) SR e , -C (NR e ) NR f R g , -C (S) R e , -C (S) OR e , -C (S) NR f R g , -OR e , -OC (O) R e , -OC (O) OR e , -OC (O) NR f R g , -OC (O)
  • composition comprising a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and a pharmaceutically acceptable excipient.
  • a method of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a method of treating, preventing, or ameliorating one or more symptoms of a proliferative disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a method of inhibiting the growth of a cell comprising contacting the cell with an effective amount of a compound of Formula (I) , or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.
  • a method of treating, preventing, or ameliorating one or more symptoms of a fibrotic disease in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a compound of Formula (I-A) :
  • R 1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl;
  • R 2 is -CN, -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , -OR 2a , -NR 2b R 2c , or heteroaryl; wherein R 2a , R 2b , and R 2c are each independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl;
  • R 3 , R 4 , R 5 , and R 6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C (O) R 1a , -C (O) OR 1a , -C (O) NR 1b R 1c , -C (NR 1a ) NR 1b R 1c , -OR 1a , -OC (O) R 1a , -OC (O) OR 1a , -OC (O) NR 1b R 1c , -OC (NR 1a ) NR 1b R 1c , -OS (O) R 1a , -OS (O) 2 R 1a , -OS (O) NR
  • each R 7 is independently (a) deuterium, cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C (O) R 1a , -C (O) OR 1a , -C (O) NR 1b R 1c , -C (NR 1a ) NR 1b R 1c , -OR 1a , -OC (O) R 1a , -OC (O) OR 1a , -OC (O) NR 1b R 1c , -OC (NR 1a ) NR 1b R 1c , -OS (O) R 1a , -OS (O) 2 R 1a , -OS (O) NR 1b R 1c , -OS (O) 2
  • R C is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -OR 1a , -NR 1b R 1c , or-NR 1a C (O) R 1d ;
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • n is an integer of 0, 1, 2, 3, or 4;
  • each R 1a , R 1b , R 1c , and R 1d is independently hydrogen, deuterium, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or R 1a and R 1c together with the C and N atoms to which they are attached form heterocyclyl; or R 1b and R 1c together with the N atom to which they are attached form heterocyclyl;
  • each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; and (c) -C (O) R a , -C (O) OR a , -C (O) NR b R c , -
  • each Q a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) -C (O) R e , -C (O) OR e , -C (O) NR f R g , -C (O) SR e , -C (NR e ) NR f R g , -C (S) R e , -C (S) OR e , -C (S) NR f R g , -OR e , -OC (O) R e , -OC (O) OR e , -OC (O) NR f R g , -OC (O)
  • FIG. 1 shows the effect of malotilate (Mal) , and compounds A11 and B9 on body weight in C57/BL6 mice.
  • FIG. 2 shows the effect of Mal, and compounds A11 and B9 on the mRNA level of ⁇ -SMA in C57/BL6 mice.
  • FIG. 3 shows the effect of Mal, and compounds A11 and B9 on the mRNA level of Col1a1 in C57/BL6 mice.
  • FIG. 4 shows Sirius red pathological staining images of the liver samples of C57/BL6 mice treated with Mal, or compound A11 or B9, indicating that each compound reversed the fibrosis induced by CCl 4 .
  • FIG. 5 shows the effect of Mal and compound A23 on the mRNA level of ⁇ -SMA in C57/BL6 mice.
  • FIG. 6 shows the effect of Mal and compound A23 on the mRNA level of Col1a1 in C57/BL6 mice.
  • subject refers to an animal, including, but not limited to, a primate (e.g., human) , cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse.
  • primate e.g., human
  • subject and patient are used interchangeably herein in reference, for example, to a mammalian subject, such as a human subject. In one embodiment, the subject is a human.
  • treat, ” “treating, ” and “treatment” are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or alleviating or eradicating the cause (s) of the disorder, disease, or condition itself.
  • prevent, ” and “prevention” are meant to include a method of delaying and/or precluding the onset of a disorder, disease, or condition, and/or its attendant symptoms; barring a subject from acquiring a disorder, disease, or condition; or reducing a subject’s risk of acquiring a disorder, disease, or condition.
  • alleviate and “alleviating” refer to easing or reducing one or more symptoms (e.g., pain) of a disorder, disease, or condition.
  • the terms can also refer to reducing adverse effects associated with an active ingredient.
  • the beneficial effects that a subject derives from a prophylactic or therapeutic agent do not result in a cure of the disorder, disease, or condition.
  • contacting or “contact” is meant to refer to bringing together of a therapeutic agent and a biological molecule (e.g., a protein, enzyme, RNA, or DNA) , cell, or tissue such that a physiological and/or chemical effect takes place as a result of such contact. Contacting can take place in vitro, ex vivo, or in vivo.
  • a therapeutic agent is contacted with a biological molecule in vitro to determine the effect of the therapeutic agent on the biological molecule.
  • a therapeutic agent is contacted with a cell in cell culture (in vitro) to determine the effect of the therapeutic agent on the cell.
  • the contacting of a therapeutic agent with a biological molecule, cell, or tissue includes the administration of a therapeutic agent to a subject having the biological molecule, cell, or tissue to be contacted.
  • terapéuticaally effective amount or “effective amount” is meant to include the amount of a compound that, when administered, is sufficient to prevent development of, or alleviate to some extent, one or more of the symptoms of the disorder, disease, or condition being treated.
  • therapeutically effective amount or “effective amount” also refers to the amount of a compound that is sufficient to elicit a biological or medical response of a biological molecule (e.g., a protein, enzyme, RNA, or DNA) , cell, tissue, system, animal, or human, which is being sought by a researcher, veterinarian, medical doctor, or clinician.
  • a biological molecule e.g., a protein, enzyme, RNA, or DNA
  • pharmaceutically acceptable carrier refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material.
  • each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of a subject (e.g., a human) without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, and commensurate with a reasonable benefit/risk ratio.
  • the term “about” or “approximately” means an acceptable error for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined. In certain embodiments, the term “about” or “approximately” means within 1, 2, or 3 standard deviations. In certain embodiments, the term “about” or “approximately” means within 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.05%of a given value or range.
  • alkyl refers to a linear or branched saturated monovalent hydrocarbon radical, wherein the alkyl is optionally substituted with one or more substituents Q as described herein.
  • C 1-6 alkyl refers to a linear saturated monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkyl is a linear saturated monovalent hydrocarbon radical that has 1 to 20 (C 1-20 ) , 1 to 15 (C 1-15 ) , 1 to 10 (C 1-10 ) , or 1 to 6 (C 1-6 ) carbon atoms, or branched saturated monovalent hydrocarbon radical of 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • linear C 1-6 and branched C 3-6 alkyl groups are also referred as “lower alkyl.
  • alkyl groups include, but are not limited to, methyl, ethyl, propyl (including all isomeric forms, e.g., n-propyl and isopropyl) , butyl (including all isomeric forms, e.g., n-butyl, isobutyl, sec-butyl, and t-butyl) , pentyl (including all isomeric forms, e.g., n-pentyl, isopentyl, sec-pentyl, neopentyl, and tert-pentyl) , and hexyl (including all isomeric forms, e.g., n-hexyl, isohexyl, and sec-hexyl) .
  • alkylene and “alkanediyl” are used interchangeably herein in reference to a linear or branched saturated divalent hydrocarbon radical, wherein the alkylene is optionally be substituted with one or more substituents Q as described herein.
  • C 1-6 alkylene refers to a linear saturated divalent hydrocarbon radical of 1 to 6 carbon atoms or a branched saturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkylene is a linear saturated divalent hydrocarbon radical that has 1 to 30 (C 1-30 ) , 1 to 20 (C 1- 20 ) , 1 to 15 (C 1-15 ) , 1 to 10 (C 1-10 ) , or 1 to 6 (C 1-6 ) carbon atoms, or branched saturated divalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3- 6 ) carbon atoms.
  • linear C 1-6 and branched C 3-6 alkylene groups are also referred as “lower alkylene.
  • alkylene groups include, but are not limited to, methylene, ethylene (including all isomeric forms, e.g., ethan-1, 1-diyl and ethan-1, 2-diyl) , propylene (including all isomeric forms, e.g., propan-1, 1-diyl, propan-1, 2-diyl, and propan-1, 3-diyl) , butylene (including all isomeric forms, e.g., butan-1, 1-diyl, butan-1, 2-diyl, butan-1, 3-diyl, and butan-1, 4-diyl) , pentylene (including all isomeric forms, e.g., pentan-1, 1-diyl, pentan-1, 2-diyl, pentan-1, 3-diyl, and pentan-1, 5-diyl) , and hexylene (including all isomeric forms, e.g.,
  • alkenyl refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond (s) .
  • the alkenyl is optionally substituted with one or more substituents Q as described herein.
  • alkenyl embraces radicals having a “cis” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art.
  • C 2-6 alkenyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkenyl is a linear monovalent hydrocarbon radical of 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched monovalent hydrocarbon radical of 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • alkenyl groups include, but are not limited to, ethenyl, propenyl (including all isomeric forms, e.g., propen-1-yl, propen-2-yl, and allyl) , and butenyl (including all isomeric forms, e.g., buten-1-yl, buten-2-yl, buten-3-yl, and 2-buten-1-yl) .
  • alkenylene and “alkenediyl” are used interchangeably herein in reference to a linear or branched divalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon double bond (s) .
  • the alkenylene is optionally substituted with one or more substituents Q as described herein.
  • alkenylene embraces radicals having a “cis” or “trans” configuration or a mixture thereof, or alternatively, a “Z” or “E” configuration or a mixture thereof, as appreciated by those of ordinary skill in the art.
  • C 2-6 alkenylene refers to a linear unsaturated divalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated divalent hydrocarbon radical of 3 to 6 carbon atoms.
  • the alkenylene is a linear divalent hydrocarbon radical of 2 to 30 (C 2-30 ) , 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched divalent hydrocarbon radical of 3 to 30 (C 3-30 ) , 3 to 20 (C 3-20 ) , 3 to 15 (C 3-15 ) , 3 to 10 (C 3-10 ) , or 3 to 6 (C 3-6 ) carbon atoms.
  • alkenylene groups include, but are not limited to, ethenylene (including all isomeric forms, e.g., ethen-1, 1-diyl or ethen-1, 2-diyl) , propenylene (including all isomeric forms, e.g., 1-propen-1, 1-diyl, 1-propen-1, 2-diyl, and 1-propen-1, 3-diyl) , butenylene (including all isomeric forms, e.g., 1-buten-1, 1-diyl, 1-buten-1, 2-diyl, and 1-buten-1, 4-diyl) , pentenylene (including all isomeric forms, e.g., 1-penten-1, 1-diyl, 1-penten-1, 2-diyl, and 1-penten-1, 5-diyl) , and hexenylene (including all isomeric forms, e.g., 1-hexen-1, 1-diyl)
  • alkynyl refers to a linear or branched monovalent hydrocarbon radical, which contains one or more, in one embodiment, one, two, three, or four, in another embodiment, one, carbon-carbon triple bond (s) .
  • the alkynyl is optionally substituted with one or more substituents Q as described herein.
  • C 2-6 alkynyl refers to a linear unsaturated monovalent hydrocarbon radical of 2 to 6 carbon atoms or a branched unsaturated monovalent hydrocarbon radical of 4 to 6 carbon atoms.
  • the alkynyl is a linear monovalent hydrocarbon radical of 2 to 20 (C 2-20 ) , 2 to 15 (C 2-15 ) , 2 to 10 (C 2-10 ) , or 2 to 6 (C 2-6 ) carbon atoms, or a branched monovalent hydrocarbon radical of 4 to 20 (C 4-20 ) , 4 to 15 (C 4-15 ) , 4 to 10 (C 4-10 ) , or 4 to 6 (C 4-6 ) carbon atoms.
  • cycloalkyl refers to a cyclic monovalent hydrocarbon radical, which is optionally substituted with one or more substituents Q as described herein.
  • the cycloalkyl is a saturated or unsaturated but non-aromatic, and/or bridged or non-bridged, and/or fused bicyclic group.
  • the cycloalkyl has from 3 to 20 (C 3-20 ) , from 3 to 15 (C 3-15 ) , from 3 to 10 (C 3-10 ) , or from 3 to 7 (C 3-7 ) carbon atoms.
  • the cycloalkyl is monocyclic.
  • the cycloalkyl is bicyclic.
  • the cycloalkyl is tricyclic. In still another embodiment, the cycloalkyl is polycyclic. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptenyl, bicyclo [1.1.1] pentyl, bicyclo [2.1.1] hexyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl, decalinyl, and adamantyl.
  • cycloalkylene and “cycloalkanediyl” are used interchangeably herein in reference to a cyclic divalent hydrocarbon radical, which may be optionally substituted with one or more substituents Q as described herein.
  • cycloalkyl groups may be saturated or unsaturated but non-aromatic, and/or bridged, and/or non-bridged, and/or fused bicyclic groups.
  • the cycloalkylene has from 3 to 30 (C 3-30 ) , 3 to 20 (C 3- 20 ) , from 3 to 15 (C 3-15 ) , from 3 to 10 (C 3-10 ) , or from 3 to 7 (C 3-10 ) carbon atoms.
  • cycloalkylene groups include, but are not limited to, cyclopropylene (including all isomeric forms, e.g., cycloprop-1, 1-diyl and cycloprop-1, 2-diyl) , cyclobutylene (including all isomeric forms, e.g., cyclobut-1, 1-diyl, cyclobut-1, 2-diyl, and cyclobut-1, 3-diyl) , cyclopentylene (including all isomeric forms, e.g., cyclopent-1, 1-diyl, cyclopent-1, 2-diyl, and cyclopent-1, 3-diyl) , cyclohexylene (including all isomeric forms, e.g., cyclohex-1, 1-diyl, cyclohex-1, 2-diyl, cyclohex-1, 3-diyl, and cyclohex-1, 4-diyl)
  • aryl refers to a monovalent monocyclic aromatic hydrocarbon radical and/or monovalent polycyclic aromatic hydrocarbon radical that contain at least one aromatic carbon ring. In certain embodiments, the aryl has from 6 to 20 (C 6-20 ) , from 6 to 15 (C 6-15 ) , or from 6 to 10 (C 6-10 ) ring carbon atoms. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, fluorenyl, azulenyl, anthryl, phenanthryl, pyrenyl, biphenyl, and terphenyl.
  • the aryl also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthyl, indenyl, indanyl, or tetrahydronaphthyl (tetralinyl) .
  • the aryl is monocyclic.
  • the aryl is bicyclic.
  • the aryl is tricyclic.
  • the aryl is polycyclic.
  • the aryl is optionally substituted with one or more substituents Q as described herein.
  • arylene and “arenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic hydrocarbon radical or divalent polycyclic aromatic hydrocarbon radical that contains at least one aromatic hydrocarbon ring.
  • the arylene has from 6 to 20 (C 6-20 ) , from 6 to 15 (C 6-15 ) , or from 6 to 10 (C 6-10 ) ring atoms.
  • arylene groups include, but are not limited to, phenylene (including all isomeric forms, e.g., phen-1, 2-diyl, phen-1, 3-diyl, and phen-1, 4-diyl) , naphthylene (including all isomeric forms, e.g., naphth-1, 2-diyl, naphth-1, 3-diyl, and naphth-1, 8-diyl) , fluorenylene (including all isomeric forms, e.g., fluoren-1, 2-diyl, fluoren-1, 3-diyl, and fluoren-1, 8-diyl) , azulenylene (including all isomeric forms, e.g., azulen-1, 2-diyl, azulen-1, 3-diyl, and azulen-1, 8-diyl) , anthrylene (including all isomeric forms, e.
  • Arylene also refers to bicyclic or tricyclic carbon rings, where one of the rings is aromatic and the others of which may be saturated, partially unsaturated, or aromatic, for example, dihydronaphthylene (including all isomeric forms, e.g., dihydronaphth-1, 2-diyl or dihydronaphth-1, 8-diyl) , indenylene (including all isomeric forms, e.g., inden-1, 2-diyl, inden-1, 5-diyl, or inden-1, 7-diyl) , indanylene (including all isomeric forms, e.g., indan-1, 2-diyl, indan-1, 5-diyl, or indan-1, 7-diyl) , or tetrahydronaphthylene (tetralinylene) (including all isomeric forms, e.g., tetrahydronaphth-1, 2-di
  • aralkyl or “arylalkyl” refers to a monovalent alkyl group substituted with one or more aryl groups. In certain embodiments, the aralkyl has from 7 to 30 (C 7-30 ) , from 7 to 20 (C 7-20 ) , or from 7 to 16 (C 7-16 ) carbon atoms.
  • aralkyl groups include, but are not limited to, benzyl, phenylethyl (including all isomeric forms, e.g., 1-phenylethyl and 2-phenylethyl) , and phenylpropyl (including all isomeric forms, e.g., 1-phenylpropyl, 2-phenylpropyl, and 3-phenylpropyl) .
  • the aralkyl is optionally substituted with one or more substituents Q as described herein.
  • heteroaryl refers to a monovalent monocyclic aromatic group or monovalent polycyclic aromatic group that contain at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms, each independently selected from O, S, and N, in the ring.
  • the heteroaryl is bonded to the rest of a molecule through the aromatic ring.
  • Each ring of a heteroaryl group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms; provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the heteroaryl has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms.
  • the heteroaryl is monocyclic.
  • monocyclic heteroaryl groups include, but are not limited to, furanyl, imidazolyl, isothiazolyl, isoxazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, tetrazolyl, triazinyl, and triazolyl.
  • the heteroaryl is bicyclic.
  • bicyclic heteroaryl groups include, but are not limited to, benzofuranyl, benzimidazolyl, benzoisoxazolyl, benzopyranyl, benzothiadiazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, furopyridyl, imidazopyridinyl, imidazothiazolyl, indolizinyl, indolyl, indazolyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, oxazolopyridinyl, phthalazinyl, pteridinyl, purinyl, pyridopyridyl, pyrrolopyridyl, quinolinyl, quinoxalinyl, quinazolinyl, thiadiazolopyrimi
  • the heteroaryl is tricyclic.
  • tricyclic heteroaryl groups include, but are not limited to, acridinyl, benzindolyl, carbazolyl, dibenzofuranyl, perimidinyl, phenanthrolinyl, phenanthridinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxazinyl, and xanthenyl.
  • the heteroaryl is optionally substituted with one or more substituents Q as described herein.
  • heteroarylene and “heteroarenediyl” are used interchangeably herein in reference to a divalent monocyclic aromatic group or divalent polycyclic aromatic group that contains at least one aromatic ring, wherein at least one aromatic ring contains one or more heteroatoms in the ring, each of which is independently selected from O, S, and N.
  • a heteroarylene group has at least one linkage to the rest of a molecule via its aromatic ring (s) .
  • Each ring of a heteroarylene group can contain one or two O atoms, one or two S atoms, and/or one to four N atoms, provided that the total number of heteroatoms in each ring is four or less and each ring contains at least one carbon atom.
  • the heteroarylene has from 5 to 20, from 5 to 15, or from 5 to 10 ring atoms.
  • Examples ofmonocyclic heteroarylene groups include, but are not limited to, furanylene, imidazolylene, isothiazolylene, isoxazolylene, oxadiazolylene, oxadiazolylene, oxazolylene, pyrazinylene, pyrazolylene, pyridazinylene, pyridylene, pyrimidinylene, pyrrolylene, thiadiazolylene, thiazolylene, thienylene, tetrazolylene, triazinylene, and triazolylene.
  • bicyclic heteroarylene groups include, but are not limited to, benzofuranylene, benzimidazolylene, benzoisoxazolylene, benzopyranylene, benzothiadiazolylene, benzothiazolylene, benzothienylene, benzotriazolylene, benzoxazolylene, furopyridylene, imidazopyridinylene, imidazothiazolylene, indolizinylene, indolylene, indazolylene, isobenzofuranylene, isobenzothienylene, isoindolylene, isoquinolinylene, isothiazolylene, naphthyridinylene, oxazolopyridinylene, phthalazinylene, pteridinylene, purinylene, pyridopyridylene, pyrrolopyridylene, quinolinylene, quinoxalinylene, quinazolinylene, thiadiazolopyrimi
  • tricyclic heteroarylene groups include, but are not limited to, acridinylene, benzindolylene, carbazolylene, dibenzofuranylene, perimidinylene, phenanthrolinylene, phenanthridinylene, phenarsazinylene, phenazinylene, phenothiazinylene, phenoxazinylene, and xanthenylene.
  • heteroarylene is optionally substituted with one or more substituents Q as described herein.
  • heterocyclyl refers to a monovalent monocyclic non-aromatic ring system or monovalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms, each independently selected from O, S, and N; and the remaining ring atoms are carbon atoms.
  • the heterocyclyl or heterocyclic group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms.
  • the heterocyclyl is bonded to the rest of a molecule through the non-aromatic ring.
  • the heterocyclyl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic.
  • the heterocyclyl may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.
  • heterocyclyls and heterocyclic groups include, but are not limited to, azepinyl, benzodioxanyl, benzodioxolyl, benzofuranonyl, benzopyranonyl, benzopyranyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzoxazinyl, ⁇ -carbolinyl, chromanyl, chromonyl, cinnolinyl, coumarinyl, decahydroisoquinolinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrofuryl, dihydroisoindolyl, dihydropyranyl, dihydropyrazolyl, dihydropyrazinyl, dihydropyridinyl, dihydropyrimidinyl, dihydropyrrolyl, dioxolanyl, 1, 4-d
  • heterocyclylene refers to a divalent monocyclic non-aromatic ring system or divalent polycyclic ring system that contains at least one non-aromatic ring, wherein one or more of the non-aromatic ring atoms are heteroatoms independently selected from O, S, and N; and the remaining ring atoms are carbon atoms.
  • Heterocyclylene groups are bonded to the rest of a molecule through the non-aromatic ring.
  • the heterocyclylene group has from 3 to 20, from 3 to 15, from 3 to 10, from 3 to 8, from 4 to 7, or from 5 to 6 ring atoms.
  • the heterocyclylene is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may be fused or bridged, and in which nitrogen or sulfur atoms may be optionally oxidized, nitrogen atoms may be optionally quaternized, and some rings may be partially or fully saturated, or aromatic.
  • the heterocyclylene may be attached to the main structure at any heteroatom or carbon atom which results in the creation of a stable compound.
  • heterocyclylene groups include, but are not limited to, azepinylene, benzodioxanylene, benzodioxolylene, benzofuranonylene, benzopyranonylene, benzopyranylene, benzotetrahydrofuranylene, benzotetrahydrothienylene, benzothiopyranylene, benzoxazinylene, ⁇ -carbolinylene, chromanylene, chromonylene, cinnolinylene, coumarinylene, decahydroisoquinolinylene, dihydrobenzisothiazinylene, dihydrobenzisoxazinylene, dihydrofurylene, dihydroisoindolylene, dihydropyranylene, dihydropyrazolylene, dihydropyrazinylene, dihydropyridinylene, dihydropyrimidinylene, dihydropyrrolylene, dioxolanylene, 1, 4-dithiany
  • halogen refers to fluoro, chloro, bromo, and/or iodo.
  • each Q a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) -C (O) R e , -C (O) OR e , -C (O) NR f R g , C (O) SR e , -C (NR e ) NR f R g , -C (S) R e , -C (S) OR e , -C (S) MR f R g , -OR e , -OC (O) R e , -OC (O) OR e , -OC (O) NR f R g , -OC (O) NR
  • optically active and ” enantiomerically active refer to a collection of molecules, which has an enantiomeric excess of no less than about 80%, no less than about 90%, no less than about 91%, no less than about 92%, no less than about 93%, no less than about 94%, no less than about 95%, no less than about 96%, no less than about 97%, no less than about 98%, no less than about 99%, no less than about 99.5%, or no less than about 99.8%.
  • an optically active compound comprises about 95%or more of one enantiomer and about 5%or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.
  • an optically active compound comprises about 98%or more of one enantiomer and about 2%or less of the other enantiomer based on the total weight of the enantiomeric mixture in question. In certain embodiments, an optically active compound comprises about 99%or more of one enantiomer and about 1%or less of the other enantiomer based on the total weight of the enantiomeric mixture in question.
  • the prefixes R and S are used to denote the absolute configuration of the compound about its chiral center (s) .
  • the (+) and (-) are used to denote the optical rotation of the compound, that is, the direction in which a plane of polarized light is rotated by the optically active compound.
  • the (-) prefix indicates that the compound is levorotatory, that is, the compound rotates the plane of polarized light to the left or counterclockwise.
  • the (+) prefix indicates that the compound is dextrorotatory, that is, the compound rotates the plane of polarized light to the right or clockwise.
  • the sign of optical rotation, (+) and (-) is not related to the absolute configuration of the compound, R and S.
  • isotopically enriched refers to a compound that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a compound.
  • an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen ( 1 H) , deuterium ( 2 H) , tritium ( 3 H) , carbon-11 ( 11 C) , carbon-12 ( 12 C) , carbon-13 ( 13 C) , carbon-14 ( 14 C) , nitrogen-13 ( 13 N) , nitrogen-14 ( 14 N) , nitrogen-15 ( 15 N) , oxygen-14 ( 14 O) , oxygen-15 ( 15 O) , oxygen-16 ( 16 O) , oxygen-17 ( 17 O) , oxygen-18 ( 18 O) , fluorine-17 ( 17 F) , fluorine-18 ( 18 F) , phosphorus-31 ( 31 P) , phosphorus-32 ( 32 P) , phosphorus-33 ( 33 P) , sulfur-
  • an isotopically enriched compound is in a stable form, that is, non-radioactive.
  • an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen ( 1 H) , deuterium ( 2 H) , carbon-12 ( 12 C) , carbon-13 ( 13 C) , nitrogen-14 ( 14 N) , nitrogen-15 ( 15 N) , oxygen-16 ( 16 O) , oxygen-17 ( 17 O) , oxygen-18 ( 18 O) , fluorine-17 ( 17 F) , phosphorus-31 ( 31 P) , sulfur-32 ( 32 S) , sulfur-3 3 ( 33 S) , sulfur-34 ( 34 S) , sulfur-36 ( 36 S) , chlorine-35 ( 35 Cl) , chlorine-37 ( 37 Cl) , bromine-79 ( 79 Br) , bromine-81 ( 81 Br) , and iodine-127 ( 127 I) .
  • an isotopically enriched compound is in an unstable form, that is, radioactive.
  • an isotopically enriched compound contains unnatural proportions of one or more isotopes, including, but not limited to, tritium ( 3 H) , carbon-11 ( 11 C) , carbon-14 ( 14 C) , nitrogen-13 ( 13 N) , oxygen-14 ( 14 O) , oxygen-15 ( 15 O) , fluorine-18 ( 18 F) , phosphorus-32 ( 32 P) , phosphorus-33 ( 33 p) , sulfur-35 ( 35 S) , chlorine-36 ( 36 Cl) , iodine-123 ( 123 I) , iodine-125 ( 125 I) , iodine-129 ( 129 I) , and iodine-131 ( 131 I) .
  • any hydrogen can be 2 H, as example, or any carbon can be 13 C, as example, or any nitrogen can be 15 N, as example, or any oxygen can be 18 O, as example, where feasible according to the judgment of one of ordinary skill in the art.
  • isotopic enrichment refers to the percentage of incorporation of a less prevalent isotope (e.g., D for deuterium or hydrogen-2) of an element at a given position in a molecule in the place of a more prevalent isotope (e.g., 1 H for protium or hydrogen-1) of the element.
  • a less prevalent isotope e.g., D for deuterium or hydrogen-2
  • a more prevalent isotope e.g., 1 H for protium or hydrogen-1
  • isotopic enrichment factor refers the ratio of the isotopic abundance in an isotopically enriched compound over the natural abundance of a specific isotope.
  • hydrogen refers to the composition of naturally occurring hydrogen isotopes, which include protium ( 1 H) , deuterium ( 2 H or D) , and tritium ( 3 H) , in their natural abundances.
  • Protium is the most common hydrogen isotope having a natural abundance of more than 99.98%.
  • Deuterium is a less prevalent hydrogen isotope having a natural abundance of about 0.0156%.
  • deuterium enrichment refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of 1%at a given position means that 1%of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%on average, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%on average. As used herein, when a particular position in an isotopically enriched compound is designated as having deuterium, it is understood that the abundance of deuterium at that position in the compound is substantially greater than its natural abundance (0.0156%) .
  • carbon or the symbol “C” refers to the composition of naturally occurring carbon isotopes, which include carbon-12 ( 12 C) and carbon-13 ( 13 C) in their natural abundances.
  • Carbon-12 is the most common carbon isotope having a natural abundance of more than 98.89%.
  • Carbon-13 is a less prevalent carbon isotope having a natural abundance of about 1.11%.
  • carbon-13 enrichment or “ 13 C enrichment” refers to the percentage of incorporation of carbon-13 at a given position in a molecule in the place of carbon.
  • carbon-13 enrichment of 10%at a given position means that 10%of molecules in a given sample contain carbon-13 at the specified position. Because the naturally occurring distribution of carbon-13 is about 1.11%on average, carbon-13 enrichment at any position in a compound synthesized using non-enriched starting materials is about 1.11%on average.
  • when a particular position in an isotopically enriched compound is designated as having carbon-13, it is understood that the abundance of carbon-13 at that position in the compound is substantially greater than its natural abundance (1.11%) .
  • substantially pure and substantially homogeneous mean sufficiently homogeneous to appear free of readily detectable impurities as determined by standard analytical methods used by one of ordinary skill in the art, including, but not limited to, thin layer chromatography (TLC) , gel electrophoresis, high performance liquid chromatography (HPLC) , gas chromatography (GC) , nuclear magnetic resonance (NMR) , and mass spectrometry (MS) ; or sufficiently pure such that further purification would not detectably alter the physical, chemical, biological, and/or pharmacological properties, such as enzymatic and biological activities, of the substance.
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • GC gas chromatography
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • substantially pure or “substantially homogeneous” refers to a collection of molecules, wherein at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.5%by weight of the molecules are a single compound, including a single enantiomer, a racemic mixture, or a mixture of enantiomers, as determined by a standard analytical method.
  • a molecule that contains other than the designated isotope at the specified position is an impurity with respect to the isotopically enriched compound.
  • a deuterated compound that has an atom at a particular position designated as deuterium a compound that contains a protium at the same position is an impurity.
  • solvate refers to a complex or aggregate formed by one or more molecules of a solute, e.g., a compound provided herein, and one or more molecules of a solvent, which are present in a stoichiometric or non-stoichiometric amount.
  • Suitable solvents include, but are not limited to, water, methanol, ethanol, n-propanol, isopropanol, and acetic acid.
  • the solvent is pharmaceutically acceptable.
  • the complex or aggregate is in a crystalline form.
  • the complex or aggregate is in a noncrystalline form.
  • the solvent is water
  • the solvate is a hydrate. Examples of hydrates include, but are not limited to, a hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate, and pentahydrate.
  • an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof” has the same meaning as the phrase “ (i) an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tautomers, or an isotopic variant of the compound referenced therein; (ii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of the compound referenced therein; or (iii) a pharmaceutically acceptable salt, solvate, hydrate, or prodrug of an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, a tautomer, a mixture of two or more tauto
  • R 1 is (a) hydrogen, deuterium, cyano, halo, or nitro; or (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl;
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or heteroaryl; wherein R 2a , R 2b , and R 2c are each independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl;
  • R 3 , R 4 , R 5 , and R 6 are each independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C (O) R 1a , -C (O) OR 1a , -C (O) NR 1b R 1c , -C (NR 1a ) NR 1b R 1c , -OR 1a , -OC (O) R 1a , -OC (O) OR 1a , -OC (O) NR 1b R 1c , -OC (NR 1a ) NR 1b R 1c , -OS (O) R 1a , -OS (O) 2 R 1a , -OS (O) NR
  • R A is C 6-14 arylene or heteroarylene
  • R B is C 6-14 aryl or heteroaryl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6- 14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene, C 2-6 alkenylene, C 3-10 cycloalkylene, or heterocyclylene;
  • each R 1a , R 1b , R 1c , and R 1d is independently hydrogen, deuterium, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or R 1a and R 1c together with the C and N atoms to which they are attached form heterocyclyl; or R 1b and R 1c together with the N atom to which they are attached form heterocyclyl;
  • each alkyl, alkylene, alkenyl, alkenylene, alkynyl, cycloalkyl, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, heterocyclyl, and heterocyclylene is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q, wherein each Q is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q a ; and (c) -C (O) R a , -C (O) OR
  • each Q a is independently selected from: (a) deuterium, cyano, halo, nitro, and oxo; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, and heterocyclyl; and (c) -C (O) R e , -C (O) OR e , -C (O) NR f R g , -C (O) SR e , -C (NR e ) NR f R g , -C (S) R e , -C (S) OR e , -C (S) NR f R g , -OR e , -OC (O) R e , -OC (O) OR e , -OC (O) NR f R g , -OC (O)
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R A , R B , L, and X are each as defined herein.
  • R 1 is halo or C 1-6 alkyl
  • R 2 is -C (O) OR 2a, -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or heteroaryl, wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R A is C 6-14 arylene or heteroarylene
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene, C 2-6 alkenylene, or C 3-10 cycloalkylene;
  • each alkyl, alkylene, alkenylene, cycloalkylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or monocyclic heteroaryl, wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R A is C 6-14 arylene or monocyclic heteroarylene
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • each alkyl, alkylene, alkenylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2 is -C (O) OH, -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or 5-membered heteroaryl, wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R A is C 6-14 arylene or 6-membered heteroarylene
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • each alkyl, alkylene, alkenylene, aryl, arylene, aralkyl, heteroaryl, heteroarylene, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2 is -C (O) OH, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, -C (O) NHOH, -C (O) NH (tetrazolyl) , tetrazolyl, or 1, 2, 4-oxadiazolyl;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R A is phenylene, chloro-phenylene, methoxy-phenylene, pyridylene, or methyl-pyridylene;
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and
  • R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fiuorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • L is methylene, ethylene, or ethenylene.
  • R 1 is methyl
  • R 2 is -C (O) OH, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, -C (O) NHOH, -C (O) NH (tetrazol-5-yl) , tetrazol-5-yl, or 1, 2, 4-oxadiazol-5-yl;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R A is phen-1, 3-diyl, phen-1, 4-diyl, 2-chloro-phen-1, 4-diyl, 2-methoxy-phen-1, 4-diyl, pyrid-2, 5-diyl, or 3-methyl-pyrid-2, 5-diyl;
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or -S (O) 2 -;
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4- fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl; and L is methylene, ethan-1, 2-diyl, or ethen-1, 2-diyl.
  • Z 1 is C or N
  • each R 7a is independently (a) hydrogen, deuterium, cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C (O) R 1a , -C (O) OR 1a , -C (O) NR 1b R 1c , -C (NR 1a ) NR 1b R 1c , -OR 1a , -OC (O) R 1a , -OC (O) OR 1a , -OC (O) NR 1b R 1c , -OC (NR 1a ) NR 1b R 1c , -OS (O) R 1a , -OS (O) 2 R 1a , -OS (O) NR 1b R 1c , -OS (O
  • each R 7b is independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; and
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R 1a , R 1b , R 1c , R 1d , L, and X are each as defined herein;
  • each alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , L, X, U 1 , V 1 , W 1 , X 1 , Y 1 , and Z 1 are each as defined herein.
  • W 1 is C or N
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R 7a , R 7b , L, X, and Z 1 are each as defined herein.
  • W 1 is C or N
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R 7a , R 7b , L, X, and Z 1 are each as defined herein.
  • V 1 is C or N
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R 7a , R 7b , L, X, and Z 1 are each as defined herein.
  • V 1 is C or N
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R 7a , R 7b , L, X, and Z 1 are each as defined herein.
  • each R 7 is independently (a) deuterium, cyano, halo, or nitro; (b) C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-10 cycloalkyl, C 6-14 aryl, C 7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) -C (O) R 1a , -C (O) OR 1a , -C (O) NR 1b R 1c , -C (NR 1a ) NR 1b R 1c , -OR 1a , -OC (O) R 1a , -OC (O) OR 1a , -OC (O) NR 1b R 1c , -OC (NR 1a ) NR 1b R 1c , -OS (O) R 1a , -OS (O) 2 R 1a , -OS (O) NR 1b R 1c , -OS (O) 2
  • n is an integer of 0, 1, 2, 3, or 4;
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R B , R 1a , R 1b , R 1c , R 1d , L, and X are each as defined herein;
  • alkyl, alkenyl, alkynyl, cycloalkyl, aryl, aralkyl, heteroaryl, and heterocyclyl are each optionally substituted with one or more, in one embodiment, one, two, three, or four, substituents Q.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , L, X, and n are each as defined herein.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , L, X, and n are each as defined herein.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7a , R B , L, and X are each as defined herein.
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , L, X, and n are each as defined herein.
  • R 1 is halo or C 1-6 alkyl
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or heteroaryl, wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene, C 2-6 alkenylene, or C 3-10 cycloalkylene
  • n is an integer of 0, 1, 2, 3, or 4;
  • each alkyl, alkylene, alkenylene, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or monocyclic heteroaryl, wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • n is an integer of 0, 1, 2, 3, or 4;
  • each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2 is -C (O) OH, -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or 5-membered heteroaryl, wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • n is an integer of 0, 1, or 2;
  • each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2 is -C (O) OH, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, -C (O) NHOH, -C (O) NH (tetrazolyl) , tetrazolyl, or 1, 2, 4-oxadiazolyl;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • L is methylene, ethylene, or ethenylene
  • n is an integer of 0 or 1.
  • R 1 is methyl
  • R 2 is -C (O) OH, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, -C (O) NHOH, -C (O) NH (tetrazol-5-yl) , tetrazol-5-yl, or 1, 2, 4-oxadiazol-5-yl;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or -S (O) 2 -;
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3- cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1 -yl, piperidin-1-yl, or 4-morpholin-4-yl;
  • L is methylene, ethan-1, 2-diyl, or ethen-1, 2-diyl
  • n is an integer of 0 or 1.
  • R 1 is halo or C 1-6 alkyl
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or heteroaryl, wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene, C 2-6 alkenylene, or C 3-10 cycloalkylene;
  • each alkyl, alkylene, alkenylene, cycloalkylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2 is -C (O) OR 2a , -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or monocyclic heteroaryl, wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or -S (O) 2 -;
  • R B is C 6-14 aryl or heteroaryl
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form heteroaryl or heterocyclyl
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2 is -C (O) OH, -C (O) NR 2b R 2c , -C (O) N (R 2b ) OR 2c , or 5-membered heteroaryl, wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or -S (O) 2 -;
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • L is C 1-6 alkylene or C 2-6 alkenylene
  • each alkyl, alkylene, alkenylene, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2 is -C (O) OH, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, -C (O) NHOH, -C (O) NH (tetrazolyl) , tetrazolyl, or 1, 2, 4-oxadiazolyl;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • L is methylene, ethylene, or ethenylene.
  • R 1 is methyl
  • R 2 is -C (O) OH, -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, -C (O) NHOH, -C (O) NH (tetrazol-5-yl) , tetrazol-5-yl, or 1, 2, 4-oxadiazol-5-yl;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B and X are (i) , (ii) , or (iii) :
  • X is -O-, -S-, -S (O) -, or-S (O) 2 -;
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl;
  • L is methylene, ethan-1, 2-diyl, or ethen-1, 2-diyl.
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c ;
  • p is an integer of 1, 2, or 3;
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R 2a , R 2b , R 2c , and n are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R 2A , n, and p are each as defined herein.
  • R 1 , R B , R 4 , R 5 , R 6 , R 7 , R B , R 2A , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7a , R B , R 2A , and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R 2A , n, and p are each as defined herein.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2A is -OH, -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • n is an integer of 0, 1, or 2;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazolyl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo- fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazolyl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazol-5-yl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazol-5-yl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2A is -OH, -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazolyl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazolyl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazol-5-yl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazol-5-yl) ;
  • R 3 , R 5 , and R 6 are each independently hydrogen or deuterium
  • R 4 is hydrogen, deuterium, or fluoro
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and
  • p is an integer of 1 or 2.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , R 2A , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , R 2A , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , R 2A , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7a , R B , R X , R 2A , and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , R 2A , n, and p are each as defined herein.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2A is -OH, -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is deuterium, halo, or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • n is an integer of 0, 1, or 2;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazolyl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazol-5-yl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1 -yl, piperidin- 1-yl, or 4-morpholin-4-yl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 2A is -OR 2a , -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2a , R 2b , and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 2A is -OH, -NR 2b R 2c , or -N (R 2b ) OR 2c , wherein each R 2b and R 2c is independently hydrogen, C 1-6 alkyl, or heteroaryl;
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, halo or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazolyl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 2A is -OH, -NH 2 , -NHCH 3 , -NHCH 2 CH 2 OH, -NHOH, or-NH (tetrazol-5-yl) ;
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1 -yl, piperidin-1-yl, or 4-morpholin-4-yl;
  • p is an integer of 1 or 2.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7a , R B , U 2 , V 2 , and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or -O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or -O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is deuterium, halo, or -O-C 1-6 alkyl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • n is an integer of 0, 1, or 2;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or -O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or -O-C 1-6 alkyl
  • R B is C 6-14 aryl or heteroaryl
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, halo, or -O-C 1-6 alkyl
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • p is an integer of 1 or 2;
  • each alkyl, aryl, and heteroaryl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is chloro or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is chloro or methoxy
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B is phenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 4-methoxyphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl;
  • p is an integer of 1 or 2.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7a , R B , R X , U 2 , V 2 , and p are each as defined herein.
  • R 1 , R 3 , R 4 , R 5 , R 6 , R 7 , R B , R X , U 2 , V 2 , n, and p are each as defined herein.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or -O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7 is deuterium, halo, or -O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • n is an integer of 0, 1, 2, 3, or 4;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is deuterium, halo, or -O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • n is an integer of 0, 1, or 2;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7 is chloro or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl;
  • n is an integer of 0 or 1;
  • p is an integer of 1 or 2.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or -O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • p is an integer of 1, 2, or 3;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q.
  • R 1 is halo or C 1-6 alkyl
  • R 3 , R 4 , R 5 , and R 6 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl;
  • R 7a is hydrogen, deuterium, halo, or-O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is C 6-14 aryl or heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from (i) bromo, chloro, fluoro, and cyano; (ii) C 1-6 alkyl optionally substituted with one or more substituents Q a ; and (iii) -C (O) R a , -OR a , and -NR b R c , where each R a , R b , and R c is as defined herein.
  • R 1 is C 1-6 alkyl
  • R 3 and R 4 are each independently hydrogen, deuterium, halo, or C 1-6 alkyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, halo, or -O-C 1-6 alkyl
  • R B and R X are (i) or (ii) :
  • R B is monocyclic or bicyclic C 6-14 aryl, or monocyclic or bicyclic heteroaryl
  • R X is hydrogen, C 1-6 alkyl, C 6-14 aryl, or C 7-15 aralkyl; or
  • R B and R X together with the N atom to which they are attached form monocyclic or bicyclic heteroaryl, or monocyclic or bicyclic heterocyclyl;
  • p is an integer of 1 or 2;
  • each alkyl, aryl, aralkyl, heteroaryl, and heterocyclyl is optionally substituted with one, two, or three substituents Q, each substituent Q independently selected from bromo, chloro, fluoro, cyano, methyl, trifluoromethyl, ethyl, propyl, formyl, hydroxyl, methoxy, and amino.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, bromophenyl, fluorophenyl, cyanophenyl, methylphenyl, trifluoromethylphenyl, ethylphenyl, propylphenyl, methoxyphenyl, formylphenyl, bromo-fluorophenyl, difluorophenyl, trifluorophenyl, naphthyl, fluoropyridyl, fluoro-methylpyridyl, or quinolinyl; and R X is hydrogen, methyl, ethyl, hydroxyethyl, propyl, phenyl, fluorophenyl, formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrolidinyl, piperidinyl, morpholinyl, pyrrolyl, amino-imidazolyl, or indolyl;
  • p is an integer of 1 or 2.
  • R 1 is methyl
  • R 3 and R 4 are each independently hydrogen, deuterium, fluoro, or methyl
  • R 5 and R 6 are each independently hydrogen or deuterium
  • R 7a is hydrogen, deuterium, chloro, or methoxy
  • R B and R X are (i) or (ii) :
  • R B is phenyl, 3-bromophenyl, 4-bromophenyl, 4-fluorophenyl, 3-cyanophenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 4-ethylphenyl, 4-isopropylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-formylphenyl, 2-bromo-4-fluorophenyl, 2, 4-difluorophenyl, 2, 4, 5-trifluorophenyl, naphth-2-yl, 2-fluoropyrid-5-yl, 2-fluoro-3-methyl-pyrid-5-yl, or quinolin-5-yl; and R X is hydrogen, methyl, ethyl, 2-hydroxyethyl, n-propyl, phenyl, 4-fluorophenyl, 4-formylphenyl, or benzyl; or
  • R B and R X together with the N atom to which they are attached form pyrrol-1-yl, 2-amino-imidazol-1-yl, indol-1-yl, pyrrolidin-1-yl, piperidin-1-yl, or 4-morpholin-4-yl;
  • p is an integer of 1 or 2.
  • R 1 is hydrogen. In certain embodiments, R 1 is deuterium. In certain embodiments, R 1 is cyano. In certain embodiments, R 1 is halo. In certain embodiments, R 1 is fluoro or chloro. In certain embodiments, R 1 is nitro. In certain embodiments, R 1 is C 1-6 alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is methyl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is methyl. In certain embodiments, R 1 is C 2-6 alkenyl, optionally substituted with one or more substituents Q.
  • R 1 is C 2-6 alkynyl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is C 3-10 cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is C 6-14 aryl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is C 7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 1 is heterocyclyl, optionally substituted with one or more substituents Q.
  • R 2 is -C (O) OR 2a , wherein R 2a is as defined herein.
  • R 2 is -C (O) OH.
  • R 2 is -C (O) O-C 1-6 alkyl, wherein the alkyl is optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NR 2b R 2c , wherein R 2b and R 2c are each as defined herein.
  • R 2 is -C (O) NR 2b R 2c , wherein R 2b and R 2c are each independently (i) hydrogen; or (ii) C 1-6 alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NR 2b R 2c , wherein R 2b and R 2c are each independently (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NHR 2c , wherein R 2c is as defined herein.
  • R 2 is -C (O) NHR 2c , wherein R 2c is (i) hydrogen; or (ii) C 1-6 alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NHR 2c , wherein R 2c is (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NH 2 , -C (O) NHCH 3 , -C (O) NHCH 2 CH 2 OH, or -C (O) NH (tetrazolyl) .
  • R 2 is -C (O) N (R 2b ) OR 2c , wherein R 2b and R 2c are each as defined herein.
  • R 2 is -C (O) N (R 2b ) OR 2c , wherein R 2b and R 2c are each independently hydrogen or C 1-6 alkyl optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NHOR 2c , wherein R 2c is as defined herein.
  • R 2 is -C (O) NHOR 2c , wherein R 2c is hydrogen or C 1-6 alkyl optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NHO-C 1-6 alkyl, wherein the alkyl is optionally substituted with one or more substituents Q.
  • R 2 is -C (O) NHOH.
  • R 2 is heteroaryl, optionally substituted with one or more substituents Q.
  • R 2 is monocyclic heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 2 is 6-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 2 is 5-membered heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 2 is tetrazolyl or 1, 2, 4-oxadiazolyl, each of which is optionally substituted with one or more substituents Q. In certain embodiments, R 2 is tetrazol-5-yl or 5-hydroxyl-1, 2, 4-oxadiazol-5-yl.
  • R 3 is hydrogen. In certain embodiments, R 3 is deuterium. In certain embodiments, R 3 is cyano. In certain embodiments, R 3 is halo. In certain embodiments, R 3 is fluoro. In certain embodiments, R 3 is chloro. In certain embodiments, R 3 is nitro. In certain embodiments, R 3 is C 1-6 alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 3 is methyl. In certain embodiments, R 3 is C 2-6 alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R 3 is C 2-6 alkynyl, optionally substituted with one or more substituents Q.
  • R 3 is C 3-10 cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 3 is C 6-14 aryl, optionally substituted with one or more substituents Q. In certain embodiments, R 3 is C 7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 3 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 3 is heterocyclyl, optionally substituted with one or more substituents Q.
  • R 3 is -C (O) R 1a , wherein R 1a is as defined herein.
  • R 3 is -C (O) OR 1a , wherein R 1a is as defined herein.
  • R 3 is -C (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 3 is -C (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 3 is -OR 1a , wherein R 1a is as defined herein.
  • R 3 is methoxy.
  • R 3 is -OC (O) R 1a , wherein R 1a is as defined herein.
  • R 3 is -OC (O) OR 1a , wherein R 1a is as defined herein.
  • R 3 is -OC (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 3 is -OC (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 3 is -OS (O) R 1a , wherein R 1a is as defined herein.
  • R 3 is -OS (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 3 is -OS (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 3 is -OS (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 3 is -NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 3 is -NR 1a C (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 3 is -NR 1a C (O) OR 1d , wherein R 1a and R 1d are each as defined herein.
  • R 3 is -NR 1a C (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 3 is -NR 1a C (NR 1d ) NR 1b R 1c , wherein R 1a , R 1b , R 1c , and R 1d are each as defined herein.
  • R 3 is -NR 1a S (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 3 is -NR 1a S (O) 2 R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 3 is -NR 1a S (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 3 is -NR 1a S (O) 2 NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 3 is -SR 1a , wherein R 1a is as defined herein.
  • R 3 is -S (O) R 1a , wherein R 1a is as defined herein. In certain embodiments, R 3 is -S (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 3 is -S (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 3 is -S (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 4 is hydrogen. In certain embodiments, R 4 is deuterium. In certain embodiments, R 4 is cyano. In certain embodiments, R 4 is halo. In certain embodiments, R 4 is fluoro. In certain embodiments, R 4 is chloro. In certain embodiments, R 4 is nitro. In certain embodiments, R 4 is C 1-6 alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 4 is methyl. In certain embodiments, R 4 is C 2-6 alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R 4 is C 2-6 alkynyl, optionally substituted with one or more substituents Q.
  • R 4 is C 3-10 cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 4 is C 6-14 aryl, optionally substituted with one or more substituents Q. In certain embodiments, R 4 is C 7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 4 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 4 is heterocyclyl, optionally substituted with one or more substituents Q.
  • R 4 is -C (O) R 1a , wherein R 1a is as defined herein.
  • R 4 is -C (O) OR 1a , wherein R 1a is as defined herein.
  • R 4 is -C (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 4 is -C (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 4 is -OR 1a , wherein R 1a is as defined herein.
  • R 4 is methoxy.
  • R 4 is -OC (O) R 1a , wherein R 1a is as defined herein.
  • R 4 is -OC (O) OR 1a , wherein R 1a is as defined herein.
  • R 4 is -OC (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 4 is -OC (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 4 is -OS (O) R 1a , wherein R 1a is as defined herein.
  • R 4 is -OS (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 4 is -OS (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 4 is -OS (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 4 is -NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 4 is -NR 1a C (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 4 is -NR 1a C (O) OR 1d , wherein R 1a and R 1d are each as defined herein.
  • R 4 is -NR 1a C (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 4 is -NR 1a C (NR 1d ) NR 1b R 1c , wherein R1 a , R 1b , R 1c , and R 1d are each as defined herein.
  • R 4 is -NR 1a S (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 4 is -NR 1a S (O) 2 R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 4 is -NR 1a S (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 4 is -NR 1a S (O) 2 NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 4 is -SR 1a , wherein R 1a is as defined herein.
  • R 4 is -S (O) R 1a , wherein R 1a is as defined herein. In certain embodiments, R 4 is -S (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 4 is -S (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 4 is -S (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 5 is hydrogen. In certain embodiments, R 5 is deuterium. In certain embodiments, R 5 is cyano. In certain embodiments, R 5 is halo. In certain embodiments, R 5 is fluoro. In certain embodiments, R 5 is chloro. In certain embodiments, R 5 is nitro. In certain embodiments, R 5 is C 1-6 alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 5 is methyl. In certain embodiments, R 5 is C 2-6 alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R 5 is C 2-6 alkynyl, optionally substituted with one or more substituents Q.
  • R 5 is C 3-10 cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 5 is C 6-14 aryl, optionally substituted with one or more substituents Q. In certain embodiments, R 5 is C 7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 5 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 5 is heterocyclyl, optionally substituted with one or more substituents Q.
  • R 5 is -C (O) R 1a , wherein R 1a is as defined herein.
  • R 5 is -C (O) OR 1a , wherein R 1a is as defined herein.
  • R 5 is -C (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 5 is -C (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 5 is -OR 1a , wherein R 1a is as defined herein.
  • R 5 is methoxy.
  • R 5 is -OC (O) R 1a , wherein R 1a is as defined herein.
  • R 5 is -OC (O) OR 1a , wherein R 1a is as defined herein.
  • R 5 is -OC (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 5 is -OC (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 5 is -OS (O) R 1a , wherein R 1a is as defined herein.
  • R 5 is -OS (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 5 is -OS (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 5 is -OS (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 5 is -NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 5 is -NR 1a C (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 5 is -NR 1a C (O) OR 1d , wherein R 1a and R 1d are each as defined herein.
  • R 5 is -NR 1a C (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 5 is -NR 1a C (NR 1d ) NR 1b R 1c , wherein R 1a , R 1b , R 1c , and R 1d are each as defined herein.
  • R 5 is -NR 1a S (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 5 is -NR 1a S (O) 2 R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 5 is -NR 1a S (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 5 is -NR 1a S (O) 2 NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 5 is -SR 1a , wherein R 1a is as defined herein.
  • R 5 is -S (O) R 1a , wherein R 1a is as defined herein. In certain embodiments, R 5 is -S (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 5 is -S (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 5 is -S (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 6 is hydrogen. In certain embodiments, R 6 is deuterium. In certain embodiments, R 6 is cyano. In certain embodiments, R 6 is halo. In certain embodiments, R 6 is fluoro. In certain embodiments, R 6 is chloro. In certain embodiments, R 6 is nitro. In certain embodiments, R 6 is C 1-6 alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 6 is methyl. In certain embodiments, R 6 is C 2-6 alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R 6 is C 2-6 alkynyl, optionally substituted with one or more substituents Q.
  • R 6 is C 3-10 cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 6 is C 6-14 aryl, optionally substituted with one or more substituents Q. In certain embodiments, R 6 is C 7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 6 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 6 is heterocyclyl, optionally substituted with one or more substituents Q.
  • R 6 is -C (O) R 1a , wherein R 1a is as defined herein.
  • R 6 is -C (O) OR 1a , wherein R 1a is as defined herein.
  • R 6 is -C (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 6 is -C (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 6 is -OR 1a , wherein R 1a is as defined herein.
  • R 6 is methoxy.
  • R 6 is -OC (O) R 1a , wherein R 1a is as defined herein.
  • R 6 is -OC (O) OR 1a , wherein R 1a is as defined herein.
  • R 6 is -OC (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 6 is -OC (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 6 is -OS (O) R 1a , wherein R 1a is as defined herein.
  • R 6 is -OS (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 6 is -OS (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 6 is -OS (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 6 is -NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 6 is -NR 1a C (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 6 is -NR 1a C (O) OR 1d , wherein R 1a and R 1d are each as defined herein.
  • R 6 is -NR 1a C (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 6 is -NR 1a C (NR 1d ) NR 1b R 1c , wherein R 1a , R 1b , R 1c , and R 1d are each as defined herein.
  • R 6 is -NR 1a S (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 6 is -NR 1a S (O) 2 R 1d , wherein R 1a and R 1d are each as defined herein. In certain embodiments, R 6 is -NR 1a S (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein. In certain embodiments, R 6 is -NR 1a S (O) 2 NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein. In certain embodiments, R 6 is -SR 1a , wherein R 1a is as defined herein.
  • R 6 is -S (O) R 1a , wherein R 1a is as defined herein. In certain embodiments, R 6 is -S (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 6 is -S (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 6 is -S (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 7 is deuterium. In certain embodiments, R 7 is cyano. In certain embodiments, R 7 is halo. In certain embodiments, R 7 is fluoro. In certain embodiments, R 7 is chloro. In certain embodiments, R 7 is nitro. In certain embodiments, R 7 is C 1-6 alkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 7 is methyl. In certain embodiments, R 7 is C 2-6 alkenyl, optionally substituted with one or more substituents Q. In certain embodiments, R 7 is C 2-6 alkynyl, optionally substituted with one or more substituents Q.
  • R 7 is C 3-10 cycloalkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 7 is C 6-14 aryl, optionally substituted with one or more substituents Q. In certain embodiments, R 7 is C 7-15 aralkyl, optionally substituted with one or more substituents Q. In certain embodiments, R 7 is heteroaryl, optionally substituted with one or more substituents Q. In certain embodiments, R 7 is heterocyclyl, optionally substituted with one or more substituents Q.
  • R 7 is -C (O) R 1a , wherein R 1a is as defined herein.
  • R 7 is -C (O) OR 1a , wherein R 1a is as defined herein.
  • R 7 is -C (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 7 is -C (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 7 is -OR 1a , wherein R 1a is as defined herein.
  • R 7 is methoxy.
  • R 7 is -OC (O) R 1a , wherein R 1a is as defined herein.
  • R 7 is -OC (O) OR 1a , wherein R 1a is as defined herein.
  • R 7 is -OC (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 7 is -OC (NR 1a ) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 7 is -OS (O) R 1a , wherein R 1a is as defined herein.
  • R 7 is -OS (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 7 is -OS (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 7 is -OS (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 7 is -NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 7 is -NR 1a C (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 7 is -NR 1a C (O) OR 1d , wherein R 1a and R 1d are each as defined herein.
  • R 7 is -NR 1a C (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 7 is -NR 1a C (NR 1d ) NR 1b R 1c , wherein R 1a , R 1b , R 1c , and R 1d are each as defined herein.
  • R 7 is -NR 1a S (O) R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 7 is -NR 1a S (O) 2 R 1d , wherein R 1a and R 1d are each as defined herein.
  • R 7 is -NR 1a S (O) NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 7 is -NR 1a S (O) 2 NR 1b R 1c , wherein R 1a , R 1b , and R 1c are each as defined herein.
  • R 7 is -SR 1a , wherein R 1a is as defined herein.
  • R 7 is -S (O) R 1a , wherein R 1a is as defined herein. In certain embodiments, R 7 is -S (O) 2 R 1a , wherein R 1a is as defined herein. In certain embodiments, R 7 is -S (O) NR 1b R 1c , wherein R 1b and R 1c are each as defined herein. In certain embodiments, R 7 is -S (O) 2 NR 1b R 1c , wherein R 1b and R 1c are each as defined herein.
  • R 2A is -OR 2a , wherein R 2a is as defined herein. In certain embodiments, R 2A is -OH. In certain embodiments, R 2A is -O-C 1-6 alkyl, wherein the alkyl is optionally substituted with one or more substituents Q. In certain embodiments, R 2A is -NR 2b R 2c , wherein R 2b and R 2c are each as defined herein. In certain embodiments, R 2A is -NR 2b R 2c , wherein R 2b and R 2c are each independently (i) hydrogen; or (ii) C 1-6 alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q.
  • R 2A is -NR 2b R 2c , wherein R 2b and R 2c are each independently (i) hydrogen; or (ii) methyl, ethyl, or tetrazolyl, each of which is optionally substituted with one or more substituents Q.
  • R 2A is -NHR 2c , wherein R 2c is as defined herein.
  • R 2A is -NHR 2c , wherein R 2c is (i) hydrogen; or (ii) C 1-6 alkyl or heteroaryl, each of which is optionally substituted with one or more substituents Q.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
PCT/CN2021/099626 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications Ceased WO2021249529A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020237001096A KR20230024976A (ko) 2020-06-12 2021-06-11 인덴 화합물, 이의 약제학적 조성물, 및 이의 치료학적 적용
CA3182036A CA3182036A1 (en) 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
JP2022576471A JP2023529011A (ja) 2020-06-12 2021-06-11 インデン化合物、その医薬組成物、及びそれらの治療応用
CN202180055583.6A CN116472034B (zh) 2020-06-12 2021-06-11 茚化合物、其药物组合物及其治疗应用
US18/001,309 US20230234909A1 (en) 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
AU2021287932A AU2021287932A1 (en) 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
IL298984A IL298984A (en) 2020-06-12 2021-06-11 Indan compounds, their pharmaceutical preparations and their medical applications
EP21822474.9A EP4165009A4 (en) 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038737P 2020-06-12 2020-06-12
US63/038,737 2020-06-12

Publications (1)

Publication Number Publication Date
WO2021249529A1 true WO2021249529A1 (en) 2021-12-16

Family

ID=78846886

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/099626 Ceased WO2021249529A1 (en) 2020-06-12 2021-06-11 Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications

Country Status (10)

Country Link
US (1) US20230234909A1 (https=)
EP (1) EP4165009A4 (https=)
JP (1) JP2023529011A (https=)
KR (1) KR20230024976A (https=)
CN (1) CN116472034B (https=)
AU (1) AU2021287932A1 (https=)
CA (1) CA3182036A1 (https=)
IL (1) IL298984A (https=)
TW (1) TW202214555A (https=)
WO (1) WO2021249529A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022242582A1 (en) * 2021-05-15 2022-11-24 Nucmito Pharmaceuticals Company Limited Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
CN116589404A (zh) * 2023-04-24 2023-08-15 华南理工大学 一种靶向β淀粉样蛋白的光敏剂及其制备方法与应用
WO2024104384A1 (en) * 2022-11-16 2024-05-23 Nucmito Pharmaceuticals Co. Ltd. Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
WO2025051192A1 (en) * 2023-09-06 2025-03-13 Nucmito Pharmaceuticals Company Limited Rxr-alpha modulators for treating malignancy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003120A1 (en) * 1994-07-21 1996-02-08 Eli Lilly And Company INDENE sPLA2 INHIBITORS
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
DE10163426A1 (de) * 2001-12-21 2003-07-03 Max Planck Gesellschaft Pharmakologisch wirksame Inden-Derivate
WO2009090414A1 (en) * 2008-01-18 2009-07-23 Oxagen Limited Compounds having crth2 antagonist activity
WO2011140525A2 (en) * 2010-05-06 2011-11-10 Sanford-Burnham Medical Research Institute Methods and compositions related to a retinoid receptor-selective pathway

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511852A (ja) * 1997-05-07 2002-04-16 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003120A1 (en) * 1994-07-21 1996-02-08 Eli Lilly And Company INDENE sPLA2 INHIBITORS
WO1999016453A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
DE10163426A1 (de) * 2001-12-21 2003-07-03 Max Planck Gesellschaft Pharmakologisch wirksame Inden-Derivate
WO2009090414A1 (en) * 2008-01-18 2009-07-23 Oxagen Limited Compounds having crth2 antagonist activity
WO2011140525A2 (en) * 2010-05-06 2011-11-10 Sanford-Burnham Medical Research Institute Methods and compositions related to a retinoid receptor-selective pathway

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAN BAI;XIAOKAI CHEN;LIN ZHANG;XIAOGUANG DOU: "The effect of sulindac, a non-steroidal anti-inflammatory drug, attenuates inflammation and fibrosis in a mouse model of chronic pancreatitis", BMC GASTROENTEROLOGY, BIOMED CENTRAL LTD., LONDON, GB, vol. 12, no. 1, 24 August 2012 (2012-08-24), GB , pages 115, XP021120238, ISSN: 1471-230X, DOI: 10.1186/1471-230X-12-115 *
HUANG FENGYU; ZENG ZHIPING; ZHANG WEIDONG; YAN ZHIQIANG; CHEN JIAYUN; YU LIANGFA; YANG QIAN; LI YIHUAN; YU HONGYU; CHEN JUNJIE; WU: "Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 222, 24 May 2021 (2021-05-24), AMSTERDAM, NL , XP086745495, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2021.113542 *
HWU JIH RU, SHWU-CHEN TSAY, KAO SHU CHUANG, MOHIT KAPOOR, JIA YU LIN, CHEN-SHENG YEH, WU-CHOU SU, PING-CHING WU, TSUNG-LIN TSAI, P: "Syntheses of Platinum–Sulindac Complexes and Their Nanoparticles as Targeted Anticancer Drugs", CHEM. EUR. J., vol. 22, no. 6, 11 January 2016 (2016-01-11), pages 1926 - 1930, XP055879411, DOI: 10.1002/chem.201504915 *
LIU， SHUAI.: "The RXRα-mediated anti-inflammatory effect of sulindac analog K-80003 and the underlying molecular mechanism.", CHINESE DOCTORAL DISSERTATIONS & MASTER'S THESES FULL-TEXT DATABSE (MASTER) MEDICINE AND HEALTH SCIENCES., no. 6, 15 June 2019 (2019-06-15), pages 1 - 81, XP009532733 *
REDDY, VIRSINHA; JADHAV, ABHIJEET S.; VIJAYA ANAND, RAMASAMY: "Catalyst-Controlled Regioselective Approach to 1-Aminoisoquinolines and/or 1-Aminoisoindolines through Aminative Domino Cyclization of 2-Alkynylbenzonitriles.", EUROPEAN JOURNAL OF ORGANIC CHEMISTRY, vol. 2016, no. 3, 4 December 2015 (2015-12-04), pages 453 - 458, XP009532732, ISSN: 1099-0690, DOI: 10.1002/ejoc.201501390 *
See also references of EP4165009A4 *
XUE ZHOU, YOU-JIE LI, SHU-YAN GAO, XIAO-ZHI WANG, PING-YU WANG, YUN-FEI YAN, SHU-YANG XIE, CHANG-JUN LV: "Sulindac has strong antifibrotic effects by suppressing STAT3-related miR-21", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, UNIVERSITY PRESS CAROL DAVILA, BUCHAREST, RO, vol. 19, no. 5, 1 May 2015 (2015-05-01), RO , pages 1103 - 1113, XP055393488, ISSN: 1582-1838, DOI: 10.1111/jcmm.12506 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022242582A1 (en) * 2021-05-15 2022-11-24 Nucmito Pharmaceuticals Company Limited Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
WO2024104384A1 (en) * 2022-11-16 2024-05-23 Nucmito Pharmaceuticals Co. Ltd. Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
CN116589404A (zh) * 2023-04-24 2023-08-15 华南理工大学 一种靶向β淀粉样蛋白的光敏剂及其制备方法与应用
WO2025051192A1 (en) * 2023-09-06 2025-03-13 Nucmito Pharmaceuticals Company Limited Rxr-alpha modulators for treating malignancy

Also Published As

Publication number Publication date
KR20230024976A (ko) 2023-02-21
EP4165009A1 (en) 2023-04-19
IL298984A (en) 2023-02-01
AU2021287932A1 (en) 2023-02-02
CN116472034B (zh) 2026-04-17
CA3182036A1 (en) 2021-12-16
JP2023529011A (ja) 2023-07-06
CN116472034A (zh) 2023-07-21
EP4165009A4 (en) 2024-10-02
TW202214555A (zh) 2022-04-16
US20230234909A1 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
WO2021249529A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
US12516016B2 (en) GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases
US20240025863A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240368121A1 (en) Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240190883A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240190885A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20240116845A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
WO2024012557A1 (en) Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
EP4619369A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
US20230136999A1 (en) Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
US20240197888A1 (en) Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2024120442A1 (en) Pak4 protein degraders, pharmaceutical compositions, and therapeutic applications
US12419962B2 (en) Quinazolines, pharmaceutical compositions, and therapeutic applications
US10045972B2 (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US12570687B2 (en) Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating a nuclear receptor subfamily 4 group a member 1-mediated disease
WO2024104422A1 (en) Phosphorus-containing compounds for treating inflammatory bowel diesease
US20230165823A1 (en) Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
WO2025252084A1 (en) Pak4 bifunctional degraders, pharmaceutical compositions, and therapeutic applications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21822474

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3182036

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022576471

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20237001096

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202317002067

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2021822474

Country of ref document: EP

Effective date: 20230112

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021287932

Country of ref document: AU

Date of ref document: 20210611

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202180055583.6

Country of ref document: CN